1.
Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.
Mov Disord
; 8(4): 484-8, 1993 Oct.
Article
in English
| MEDLINE
| ID: mdl-8232358
ABSTRACT
We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/day, orally, and increased gradually to a maximum of 4,800 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.